Peripheral blood stem cell transplantation - Current status and issues -

Katsuto Takenaka, M. Harada

Research output: Contribution to journalArticle

Abstract

Autologous peripheral blood stem celt transplantation (auto-PBSCT) has been increasingly used in the treatment of malignant disease, and has begun to replace autologous bone marrow transplantation (autoBMT) because of rapid engraftment and low transplant-related mortality. Some clinical studies have demonstrated the safety and efficacy of high-dose chemotherapy followed by auto-PBSCT for the treatment of acute myelogenous leukemia, malignant lymphoma, multiple myeloma, and solid tumor such as breast cancer. Recently, allogeneic PBSCT (allo-PBSCT) s being evaluated as an alternative to alloBMT. Recent studies suggest that allo-PBSCT results in more rapid engraftment without an apparent increase in acute graft-versus-host disease (aGVHD) as compared to bone marrow, but further studies will be required to assess its efficacy.

Original languageEnglish
Pages (from-to)360-369
Number of pages10
JournalBiotherapy
Volume12
Issue number3
Publication statusPublished - Jan 1 1998

Fingerprint

Peripheral Blood Stem Cell Transplantation
Transplantation
Autologous Transplantation
Graft vs Host Disease
Multiple Myeloma
Bone Marrow Transplantation
Acute Myeloid Leukemia
Lymphoma
Bone Marrow
Breast Neoplasms
Transplants
Safety
Drug Therapy
Mortality
Therapeutics
Neoplasms
Clinical Studies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Takenaka, K., & Harada, M. (1998). Peripheral blood stem cell transplantation - Current status and issues -. Biotherapy, 12(3), 360-369.

Peripheral blood stem cell transplantation - Current status and issues -. / Takenaka, Katsuto; Harada, M.

In: Biotherapy, Vol. 12, No. 3, 01.01.1998, p. 360-369.

Research output: Contribution to journalArticle

Takenaka, K & Harada, M 1998, 'Peripheral blood stem cell transplantation - Current status and issues -', Biotherapy, vol. 12, no. 3, pp. 360-369.
Takenaka, Katsuto ; Harada, M. / Peripheral blood stem cell transplantation - Current status and issues -. In: Biotherapy. 1998 ; Vol. 12, No. 3. pp. 360-369.
@article{eefdc636ab2345a0a78c9fb6f442b8ac,
title = "Peripheral blood stem cell transplantation - Current status and issues -",
abstract = "Autologous peripheral blood stem celt transplantation (auto-PBSCT) has been increasingly used in the treatment of malignant disease, and has begun to replace autologous bone marrow transplantation (autoBMT) because of rapid engraftment and low transplant-related mortality. Some clinical studies have demonstrated the safety and efficacy of high-dose chemotherapy followed by auto-PBSCT for the treatment of acute myelogenous leukemia, malignant lymphoma, multiple myeloma, and solid tumor such as breast cancer. Recently, allogeneic PBSCT (allo-PBSCT) s being evaluated as an alternative to alloBMT. Recent studies suggest that allo-PBSCT results in more rapid engraftment without an apparent increase in acute graft-versus-host disease (aGVHD) as compared to bone marrow, but further studies will be required to assess its efficacy.",
author = "Katsuto Takenaka and M. Harada",
year = "1998",
month = "1",
day = "1",
language = "English",
volume = "12",
pages = "360--369",
journal = "Biotherapy",
issn = "0914-2223",
publisher = "Japanese Society for Cancer Chemotherapy",
number = "3",

}

TY - JOUR

T1 - Peripheral blood stem cell transplantation - Current status and issues -

AU - Takenaka, Katsuto

AU - Harada, M.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Autologous peripheral blood stem celt transplantation (auto-PBSCT) has been increasingly used in the treatment of malignant disease, and has begun to replace autologous bone marrow transplantation (autoBMT) because of rapid engraftment and low transplant-related mortality. Some clinical studies have demonstrated the safety and efficacy of high-dose chemotherapy followed by auto-PBSCT for the treatment of acute myelogenous leukemia, malignant lymphoma, multiple myeloma, and solid tumor such as breast cancer. Recently, allogeneic PBSCT (allo-PBSCT) s being evaluated as an alternative to alloBMT. Recent studies suggest that allo-PBSCT results in more rapid engraftment without an apparent increase in acute graft-versus-host disease (aGVHD) as compared to bone marrow, but further studies will be required to assess its efficacy.

AB - Autologous peripheral blood stem celt transplantation (auto-PBSCT) has been increasingly used in the treatment of malignant disease, and has begun to replace autologous bone marrow transplantation (autoBMT) because of rapid engraftment and low transplant-related mortality. Some clinical studies have demonstrated the safety and efficacy of high-dose chemotherapy followed by auto-PBSCT for the treatment of acute myelogenous leukemia, malignant lymphoma, multiple myeloma, and solid tumor such as breast cancer. Recently, allogeneic PBSCT (allo-PBSCT) s being evaluated as an alternative to alloBMT. Recent studies suggest that allo-PBSCT results in more rapid engraftment without an apparent increase in acute graft-versus-host disease (aGVHD) as compared to bone marrow, but further studies will be required to assess its efficacy.

UR - http://www.scopus.com/inward/record.url?scp=0031947202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031947202&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031947202

VL - 12

SP - 360

EP - 369

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 3

ER -